Cingolani, L., Barberio, B., Zingone, F., Ferronato, A., Bertani, L., Costa, F., . . . Savarino, E. V. (2021). Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. Nature Portfolio.
Style de citation Chicago (17e éd.)Cingolani, Linda, et al. Adalimumab Biosimilars, ABP501 and SB5, Are Equally Effective and Safe as Adalimumab Originator. Nature Portfolio, 2021.
Style de citation MLA (8e éd.)Cingolani, Linda, et al. Adalimumab Biosimilars, ABP501 and SB5, Are Equally Effective and Safe as Adalimumab Originator. Nature Portfolio, 2021.
Attention : ces citations peuvent ne pas être correctes à 100%.